The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback